Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide), published as a randomized controlled trial.

A 12-hour observational period was used to evaluate the following outcomes: (1) difference in incidence of headache exacerbation with migraine-like features and (2) difference in area under the curve for headache intensity scores.

Who Took Part

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

Eligible patients were aged 18 to 65 years and had a history of persistent PTH after mild TBI for at least 12 months.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.

Some participants received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.

Each person switched between CGRP (Calcitonin Gene-Related Peptide) and the comparison at some point, usually with a gap in between.

A randomized, double-blind, placebo-controlled, two-way crossover study was conducted.

What Was Measured

The subject headings attached to it are Calcitonin Gene-Related Peptide, Hypersensitivity and Post-Traumatic Headache.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Annals of neurology), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.